Additionally, the exclusion of certain comorbidities limits the broader applicability of the findings. Additional studies with larger sample sizes and more diverse populations are needed to validate SESN2 as a reliable diagnostic and prognostic marker for PCOS, particularly in relation to its role in predicting metabolic complications and cardiovascular risks. Here, SESN2 is linked to polycystic ovary syndrome.